CENTOGENE

The Rare Disease Company CENTOGENE - transforming genetic data into medical decisions.

We are one of the worldwide leaders in the field of early genetic diagnostics for rare hereditary diseases. A data repository of genetic data from over 115 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications. We focus exclusively on providing the highest quality, patient-centred service, verified by multiple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. We believe our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the world’s largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development.

11/03/2026

✨ Introducing the updated CentoCancerHereditary Portfolio 13 cancer‑type–specific panels designed for more precise and personalized care.

🔹 Pan‑Cancer Panel: 160+ genes, now more comprehensive
🔹 Cancer‑Specific Panels: Breast, CNS, Colorectal, Endocrine, Endometrial, Gastric, Hematology, Liver & Biliary, Lung, Ovarian, Pancreatic, Skin, Urology
🔹 Pathway‑Focused Panels: Precision‑driven insights for treatment guidance
🔹 Prevention Panel: For unaffected individuals seeking proactive testing

👉 Explore the new hereditary oncology portfolio on our website

08/03/2026

On International Women’s Day, we celebrate the strength, resilience, and stories of women everywhere.

Through our work at CENTOGENE, we connect with women across many different paths — colleagues, scientists, physicians, partners, and patients — each with their own journey.

Today we are proud to highlight the voices of three inspiring women from our team: Marcia Riboldi, Aida Bertoli, and Eleni Perraki, while also recognizing the many women around the world whose courage, determination, and dreams continue to shape the future of healthcare and family building.

Because every woman. Every story. Every journey, matters.

Happy International Women’s Day. 💜

03/03/2026

We were born to help diagnose patients with rare diseases - it’s in our DNA.
After 20 years of working daily to close the uncertainty gap and provide life-changing answers, we want to hear our patients’ stories first-hand.

Do you have a story to share?

If CENTOGENE has had an impact on your life or someone else’s, please share your story with us.

We would be delighted to share your story during our anniversary celebrations

Celebrating together – Fill out the form (link in bio)

hashtag hashtag hashtag hashtag hashtag hashtagguidingprecisionmedicine

28/02/2026

Today, we are joining the global community in recognizing Rare Disease Day.

Rare Disease are rare, because the individual diseases are rare – but looking at the big picture, the number of patients affected is enormous.

🌍 >350 Million people are suffering from rare disease
🙍 > 7.000 identified rare disease
🧬 80% hereditary caused by a fault in the genome
👶 50% of rare disease affected children
🎂 30% will not see their 5th birthday
👨‍⚕️ 2-3 misdiagnoses
🎯 7 years to diagnose

Every dialogue we initiate, every initiative we support, and every partnership we establish brings us closer to achieving faster diagnoses, more effective treatments and a healthcare system that is truly inclusive for all. This is our daily commitment to a shared mission.

18/02/2026

See you at the Annual Meeting of the American College of Medical Genetics and Genomics in Baltimore 🧬

📅 March 11–13
📍 Booth #316

Stop by to meet our team — and don’t miss Eleni Perraki and Jorge Pintos Basto’s presentations.
See you at !

22/01/2026

🌏 Connecting the rare disease community across Asia
We were delighted to successfully host CENTOGENE APAC conferences in Japan and Taipei, bringing together experts from pharma, biotech, healthcare, diagnostics, academia, and patient advocacy 🤝
🧬 Special thanks to Prof. Peter Bauer for his global insights, and Andy Chang for presenting CENTOGENE’s vision in the region.

16/01/2026

𝗖𝗲𝗻𝘁𝗼𝗖𝘂𝘀𝘁𝗼𝗺 𝗣𝗮𝗻𝗲𝗹 is now Bringing the Pieces Together
Full Flexibility in Panel Design - 𝗠𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟮𝟱.𝟬𝟬𝟬 𝗚𝗲𝗻𝗲𝘀 𝗔𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲
Select only the genes that are clinically relevant to your patient to ensure targeted and precise diagnostic approach!

Because each patient is unique the diagnostic approach should be too!

📄For a deeper look on this tailored service, check the new CentoCustom Panel Brochure: https://shorturl.at/94byQ

22/12/2025

✨ 𝗛𝗮𝗽𝗽𝘆 𝗛𝗼𝗹𝗶𝗱𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗖𝗘𝗡𝗧𝗢𝗚𝗘𝗡𝗘 𝗳𝗮𝗺𝗶𝗹𝘆
As the year comes to an end, we would like to thank our partners and colleagues for their trust and commitment.
We wish you a joyful holiday season and a healthy and successful year ahead. We look forward to continuing to Guide Precision Medicine together 🌍🧬

15/12/2025

CentoCustom Panel - 𝗨𝗽𝗱𝗮𝘁𝗲𝗱
As genetic knowledge evolves, providing clinicians with the flexibility to build highly targeted and comprehensive diagnostic panels is more important than ever. To support this, our offering includes 4,370 genes available for panel customization, within a total gene universe of 25,000.

29/10/2025

The Precision Medicine Tool is now updated! Our customizable genetic testing solution, 𝗖𝗲𝗻𝘁𝗼𝗖𝘂𝘀𝘁𝗼𝗺 𝗣𝗮𝗻𝗲𝗹: NOW with additional options available for including research genes.

With improved flexibility we are empowering you to design a custom gene panel tailored to each individual case with CENTOGENE’s quality and expertise in medical interpretation.

Want to Learn More?

Save the Date: November 13th. CentoCustom Panel Webinar

22/10/2025

A groundbreaking publication in Nature Communications, led by researchers from our R&D partner Fundación Carlos Simón and its biotechnology spin-off iPremom.

The study demonstrates that maternal plasma cell-free RNA (cfRNA) can accurately predict both early- and late-onset preeclampsia weeks before clinical symptoms appear — paving the way for non-invasive, subtype-specific prenatal screening.

These findings open the door to earlier and more precise detection of preeclampsia — a major step toward improving outcomes for mothers and babies worldwide — and support the clinical implementation of iPremom’s MaiRa Test for early risk stratification.

We are truly proud and grateful to collaborate with such visionary teams driving innovation in women’s health and reproductive medicine — and we look forward to continuing this journey together.

Read the full article in Nature Communications

13/10/2025

Get ready to decode Gaucher Disease! Join us for our upcoming on October 16th and explore these exciting topics with our expert speakers:

1. The Disease Background
2. Diagnosing Gaucher: The Multiomic Approach (Patient Cases)
3. Pharma Services: How We Support Clinical Trials
4. Real-World Impact: LysoProof Study

🎙️ Speakers:
Peter Bauer - Chief Medical and Genomic Officer
Eleni Perrakis, PhD - Senior Product Manager

Can’t attend the live session?
👉 Register now, and you’ll receive access to the webinar recording to watch at your convenience.

Adresse

Am Strande 7
Rostock
18055

Telefon

+4938180113416

Webseite

http://www.centogene.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von CENTOGENE erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.